

PHYLOGICA

BREAKTHROUGH PEPTIDE THERAPEUTICS

ASX Announcement

12 April 2018

Appendix 3X and 3Y

Phylogica Limited (ASX:PYC) (**Phylogica** or the **Company**), submits the following Appendices in relation to an Initial Directors interest and a Change in Director's interests:

Appendix 3X – Initial Director's Interest Notice – Mr Alan Tribe

Appendix 3Y – Change of Directors Interest Notice – Mr Bernard Hockings

Yours faithfully

Kevin Hart

Company Secretary

ENDS

About Phylogica

Phylogica Limited (ASX: PYC) is a biotech company focused on commercialising its intracellular drug delivery platform and panning its Phylomer libraries to identify drug cargoes for development against a wide range of disease targets. Phylogica controls access to the world's most structurally diverse source of peptides called Phylomers, which have the ability to act as effective drug delivery agents and drug cargoes, penetrating cell walls to reach previously 'undruggable' targets across a range of disease types. Phylogica's platform of proprietary cell penetration peptides is showing promise in delivering a diverse range of drug cargoes into cells, and the company's lead asset program has identified a phylomer which can inhibit Myc, a protein responsible for the regulation of cancer cell growth. The company has had collaborations with several pharmaceutical companies including Roche, Medimmune, Pfizer, Janssen and is currently working with Genentech.

Suite 8, 7 The Esplanade Mt Pleasant WA 6153

Tel: (08) 9316 9100 Fax: (08) 9315 5475

www.phylogica.com

ABN 48 098 391 961

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	PHYLOGICA LIMITED
ACN	098 391 961

We, Phylogica Limited give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	ALAN WILLIAM TRIBE
Date of Appointment	10 April 2018

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Number & class of securities
NIL

Appendix 3X
Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.	Number & class of Securities
Australian Land Pty Ltd Director	425,776,247 Ordinary Fully Paid Shares

Part 3 – Director's interests in contracts

Detail of contract	NIL
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	PHYLOGICA LIMITED
ABN	48 098 391 961

We, Phylogica Limited, give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	BERNARD EDWARD FREDERICK HOCKINGS
Date of last notice	19 JUNE 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	INDIRECT
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	10 APRIL 2017
No. of securities held prior to change	DIRECT - 70,018,449 ORDINARY SHARES INDIRECT <i>DR BERNARD EDWARD HOCKINGS & MRS DIANNE CHRISTINE HOCKINGS (BHOCKINGS PRIVATE S/F 2 A/C)</i> - 509,442,436 ORDINARY SHARES <i>ALEXANDRA HOCKINGS (Daughter)</i> - 2,708,172 ORDINARY SHARES <i>JAMES HOCKINGS (Son)</i> - 755,128 ORDINARY SHARES
Class	ORDINARY SHARES
Number acquired	NIL
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	OFF MARKET TRANSFER

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	265,000,000
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$7,950,000
No. of securities held after change	DIRECT - 70,018,449 ORDINARY SHARES INDIRECT <i>DR BERNARD EDWARD HOCKINGS & MRS DIANNE CHRISTINE HOCKINGS (B HOCKINGS PRIVATE S/F 2 A/C)</i> - 244,442,436 ORDINARY SHARES <i>ALEXANDRA HOCKINGS (Daughter)</i> - 2,708,172 ORDINARY SHARES JAMES HOCKINGS (Son) - 755,128 ORDINARY SHARES

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	YES
If so, was prior written clearance provided to allow the trade to proceed during this period?	YES
If prior written clearance was provided, on what date was this provided?	10/04/2018

The trade was completed inside the 24 hour post ASX release closed period with prior written approval received from the non interested directors as an exceptional circumstance in accordance with the Policy.

+ See chapter 19 for defined terms.